The CHMP recommendation is a critical step towards obtaining marketing authorisation for filgrastim biosimilar Zefylti in the European Union. Zefylti treats neutropenia and the mobilisation of peripheral progenitor cells (PBPCs). Shares of Aurobindo Pharma Ltd ended at ₹1,207.95, down by ₹7.20, or 0.59%, on the BSE.
